1
|
Garassino M, Mazieres J, Reck M, Chouaid C, Bischoff H, Reinmuth N, Cove-Smith L, Mansy T, Cortinovis D, Migliorino M, Delmonte A, Garcia Sánchez J, Chara Velarde L, Bernabe R, Paz-Ares L, Diaz Perez I, Trunova N, Foroutanpour K, Faivre-Finn C. 108MO Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in stage III, unresectable NSCLC (PACIFIC-6). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.135] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
2
|
Arkenau HT, Guthrie T, Mekhail T, Cortinovis D, Antonuzzo L, Bruce J, Gabrail N, Anderson I, Oh S, Oh S, Nott L, Shah M, Sanborn R, Oh DY, Cho J, Lin CC, Lee A, Wang Y, Wang Z, Sher A. 643TiP Open-label, phase II study of ladiratuzumab vedotin (LV) for unresectable locally advanced or metastatic solid tumors. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1156] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
3
|
Antonuzzo A, Bossi P, Cortinovis D. Elapsed time for an unresolved adverse event: systemic anticancer therapy-induced neurotoxicity calls for action. Ann Oncol 2020; 31:1289-1290. [DOI: 10.1016/j.annonc.2020.08.2103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/17/2020] [Accepted: 08/18/2020] [Indexed: 10/23/2022] Open
|
4
|
Celio L, Cortinovis D, Cogoni A, Cavanna L, Martelli O, Carnio S, Collovà E, Bertolini F, Petrelli F, Cassano A, Chiari R, Zanelli F, Vittimberga I, Letizia A, Misino A, Silvestris F, Bonizzoni E, Pilotto S, De Placido S, Bria E. 1815MO Two simplified dexamethasone (DEX)-sparing regimens with NEPA for the prevention of emesis caused by cisplatin (DDP): A phase III, controlled, non-inferiority trial. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1462] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
5
|
Gobbini E, Chiari R, Pizzutillo P, Bordi P, Ghilardi L, Pilotto S, Osman G, Cappuzzo F, Cecere F, Riccardi F, Scotti V, Martelli O, Borra G, Maiello E, Rossi A, Graziano P, Gregorc V, Casartelli C, Sergi C, Del Conte A, Delmonte A, Bareggi C, Cortinovis D, Rizzo P, Tabbò F, Rossi G, Bria E, Galetta D, Tiseo M, Di Maio M, Novello S. Real-world outcomes according to treatment strategies in ALK-rearranged non-small-cell lung cancer (NSCLC) patients: an Italian retrospective study. Clin Transl Oncol 2019; 22:294-301. [PMID: 31630357 DOI: 10.1007/s12094-019-02222-8] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2019] [Accepted: 09/27/2019] [Indexed: 12/16/2022]
Abstract
PURPOSE Anaplastic lymphoma kinase (ALK) rearrangement confers sensitivity to ALK inhibitors (ALKis) in non-small-cell lung cancer (NSCLC). Although several drugs provided an impressive outcome benefit, the most effective sequential strategy is still unknown. We describe outcomes of real-life patients according to the treatment strategy received. PATIENTS We retrospectively collected 290 ALK rearranged advanced NSCLC diagnosed between 2011 and 2017 in 23 Italian institutions. RESULTS After a median follow-up of 26 months, PFS for crizotinib and a new generation ALKis were 9.4 [CI 95% 7.9-11.2] and 11.1 months [CI 95% 9.2-13.8], respectively, while TTF were 10.2 [CI 95% 8.5-12.6] and 11.9 months [CI 95% 9.7-17.4], respectively, being consistent across the different settings. The composed outcomes (the sum of PFS or TTF) in patients treated with crizotinib followed by a new generation ALKis were 27.8 months [CI 95% 24.3-33.7] in PFS and 30.4 months [CI 95% 24.7-34.9] in TTF. The median OS from the diagnosis of advanced disease was 39 months [CI 95% 31.8-54.5]. Patients receiving crizotinib followed by a new generation ALKis showed a higher median OS [57 months (CI 95% 42.0-73.8)] compared to those that did not receive crizotinib [38 months (CI 95% 18.6-NR)] and those who performed only crizotinib as target agent [15 months (CI 95% 11.3-34.0)] (P < 0.0001). CONCLUSION The sequential administration of crizotinib and a new generation ALKis provided a remarkable clinical benefit in this real-life population, being an interesting option to consider in selected patients.
Collapse
Affiliation(s)
- E Gobbini
- Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043, Orbassano, Italy. .,Cancer Research Center Lyon, Centre Léon Bérard, 28 Rue Laennec, 69008, Lyon Cedex 08, France.
| | - R Chiari
- Oncology Unit, Santa Maria della Misericordia Hospital, Sant'Andrea delle Fratte, 6156, Perugia, Italy
| | - P Pizzutillo
- Medical Thoracic Unit, IRCCS Istituto Oncologico "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy
| | - P Bordi
- Medical Oncology Unit, University Hospital, Via Gramsci 14, 43123, Parma, Italy
| | - L Ghilardi
- Oncology Department, Papa Giovanni XXIII Hospital, Piazza OMS 1, 24127, Bergamo, Italy
| | - S Pilotto
- Oncology Unit, Department of Medicine, University of Verona, Piazzale L.A. Scuro 10, 37134, Verona, Italy
| | - G Osman
- UOSD Pneumologia Oncologica, San Camillo Forlanini Hospital, Circonvallazione Gianicolense 87, 00152, Roma, Italy
| | - F Cappuzzo
- Oncology and Hematology Department, AUSL Romagna-Ravenna, Viale Randi 5, 48100, Ravenna, Italy
| | - F Cecere
- Regina Elena National Cancer Institute, Via Elio Chianesi 53, 00144, Roma, Italy
| | - F Riccardi
- Oncology Unit, Antonio Cardarelli Hospital, Via Antonio Cardarelli 9, 80131, Napoli, Italy
| | - V Scotti
- Radiotherapy Unit, University Hospital Careggi, Largo Brambilla 3, 50134, Firenze, Italy
| | - O Martelli
- Medical Oncology Unit, San Giovanni Addolorata Hospital, Via dell'Amba Aradam 9, 00184, Rome, Italy
| | - G Borra
- Oncology Unit, East Piedmont University, Maggiore della Carità Hospital, Corso Mazzini 18, 28100, Novara, Italy
| | - E Maiello
- Department of Oncology and Hematology, Foundation IRCCS 'Casa Sollievo della Sofferenza', Viale Cappuccini 1, 71013, San Giovanni Rotondo, Italy
| | - A Rossi
- Department of Oncology and Hematology, Foundation IRCCS 'Casa Sollievo della Sofferenza', Viale Cappuccini 1, 71013, San Giovanni Rotondo, Italy
| | - P Graziano
- Department of Oncology and Hematology, Foundation IRCCS 'Casa Sollievo della Sofferenza', Viale Cappuccini 1, 71013, San Giovanni Rotondo, Italy
| | - V Gregorc
- Department of Medical Oncology, Istituto di Ricovero e Cura a Carattere Scientifico, San Raffaele Hospital, Via Olgettina Milano 60, 20132, Milano, Italy
| | - C Casartelli
- Oncology Unit, Valduce Hospital, Via Dante Alighieri 11, 22100, Como, Italy
| | - C Sergi
- Oncology Unit, A.O.R.N.A.S Garibaldi Nesima, Via Palermo 636, 95100, Catania, Italy
| | - A Del Conte
- S.O.C. Oncologia Medica e dei Tumori Immunocorrelati, Centro di Riferimento Oncologico (CRO), IRCCS, Via Gallini 2, Aviano, Italy
| | - A Delmonte
- Thoracic Oncology Group, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRCCS, Via Maroncelli 40, 47014, Meldola, Italy
| | - C Bareggi
- Oncology Unit, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Via Francesco Sforza 28, 20122, Milan, Italy
| | - D Cortinovis
- Oncology Unit, ASST San Gerardo Hospital, Via G. B. Pergolesi 33, 20052, Monza, Italy
| | - P Rizzo
- Medical Oncology Division and Breast Unit, Antonio Perrino Hospital, Strada Statale 7 per Mesagne, 72100, Brindisi, Italy
| | - F Tabbò
- Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043, Orbassano, Italy
| | - G Rossi
- Operative Unit of Pathologic Anatomy, Azienda Unità Sanitaria Locale della Romagna, Hospital St. Maria delle Croci, Viale Vincenzo Randi 5, 48121, Ravenna, Italy
| | - E Bria
- U.O.C. Oncologia Medica, Comprehensive Cancer Center, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università Cattolica del Sacro Cuore, Largo Agostino Gemelli 8, 00168, Roma, Italy
| | - D Galetta
- Medical Thoracic Unit, IRCCS Istituto Oncologico "Giovanni Paolo II", Viale Orazio Flacco 65, 70124, Bari, Italy
| | - M Tiseo
- Medical Oncology Unit, University Hospital, Via Gramsci 14, 43123, Parma, Italy
| | - M Di Maio
- Department of Oncology, University of Turin, Mauriziano Umberto I, Via Magellano 1, 10128, Turin, Italy
| | - S Novello
- Department of Oncology, University of Turin, San Luigi Gonzaga Hospital, Regione Gonzole 10, 10043, Orbassano, Italy
| |
Collapse
|
6
|
Cortellini A, Leonetti A, Catino A, Pizzutillo P, Ricciuti B, De Giglio A, Chiari R, Bordi P, Santini D, Giusti R, De Tursi M, Brocco D, Zoratto F, Rastelli F, Citarella F, Russano M, Filetti M, Marchetti P, Berardi R, Torniai M, Cortinovis D, Sala E, Maggioni C, Follador A, Macerelli M, Nigro O, Tuzi A, Iacono D, Migliorino MR, Banna G, Porzio G, Cannita K, Ferrara MG, Bria E, Galetta D, Ficorella C, Tiseo M. Osimertinib beyond disease progression in T790M EGFR-positive NSCLC patients: a multicenter study of clinicians’ attitudes. Clin Transl Oncol 2019; 22:844-851. [DOI: 10.1007/s12094-019-02193-w] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2019] [Accepted: 07/25/2019] [Indexed: 01/10/2023]
|
7
|
Gobbini E, Pizzutilo P, Chiari R, Pilotto S, Dazzi C, Osman G, Bordi P, Ghilardi L, Cecere F, Graziano P, Maiello E, Borra G, Martelli O, Gregorc V, Scotti V, Casartelli C, Riccardi F, Rizzo P, Del Conte A, Delmonte A, Bareggi C, Cortinovis D, Sergi C, Rossi A, Rossi G, Bria E, Di Maio M, Novello S. MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.539] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
8
|
Agustoni F, Yu H, Ellison K, Smith D, Mitchell P, Rivalland G, Dziadziuszko R, Gao D, Suda K, Ren S, Rivard C, Caldwell C, Rozeboom L, Brovsky K, Cortinovis D, Bidoli P, Hirsch F. MA11.05 Indoleamine 2,3-Dioxygenase Expression in Non-Small-Cell Lung Cancer: Analyses of Prevalence, Clinical Correlations and Prognostic Impact. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
9
|
Luciani A, Toschi L, Fava S, Cortinovis D, Filipazzi V, Tuzi A, Marra A, Rossi S, Rossi A, Blasi M, Violati M, Sala L, Agustoni F, Bidoli P, Zonato S, Ferrari D. Immunotherapy in elderly patients (≥ 75 yrs) with advanced non-small cell lung cancer (NSCLC): A multicenter Italian experience. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy292.094] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
10
|
Bidoli P, Stani SC, De Candis D, Cortinovis D, Parra HS, Bajetta E. Single-Agent Chemotherapy with Vinorelbine for Pretreated or Metastatic Squamous Cell Carcinoma of the Esophagus. Tumori 2018; 87:299-302. [PMID: 11765177 DOI: 10.1177/030089160108700504] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
Aims and Background At least half of the patients with squamous cell carcinoma of the esophagus (SCCE) present at diagnosis with metastatic disease, and most patients in a locally advanced phase will develop metastases despite potentially curative local therapy. Thus, the majority of patients with SCCE will become candidate for palliative chemotherapy. Only a few drugs have demonstrated moderate activity (>15%) against SCCE. The main purpose of this phase II trial was to assess the activity of vinorelbine, a semisynthetic vinca alkaloid with a wide spectrum of action, in advanced or relapsed SCCE. Methods Seventeen patients were included in the trial. Eleven of them had already received chemotherapy (cisplatin and fluorouracil) and/or radiotherapy at the time of the first diagnosis All patients were treated with vinorelbine at the dose of 30 mg/m2 every two weeks. Results Sixteen of the 17 patients enrolled in the trial were assessable for activity: partial responses were observed in 4 of the 16 (25%), and 3 of them were pretreated patients. A significant improvement of dysphagia was obtained in 4 of 11 symptomatic patients. Toxicity was mild, with only one episode of grade 4 neutropenia and constipation. Conclusions In our experience, single-agent vinorelbine is active against SCCE. It was also active in patients previously treated with cisplatin and fluorouracil. The good tolerability and the possibility of relieving symptoms such as dysphagia strongly suggest the addition of vinorelbine to combination regimens with cisplatin as front-line chemotherapy for SCCE.
Collapse
Affiliation(s)
- P Bidoli
- Medical Oncology Unit B, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy
| | | | | | | | | | | |
Collapse
|
11
|
Landi L, Chiari R, Dazzi C, Tiseo M, Chella A, Delmonte A, Bonanno L, Cortinovis D, De Marinis F, Minuti G, Buosi R, Morabito A, Spitaleri G, Gridelli C, Maione P, Galetta D, Barbieri F, Grossi F, Novello S, Bruno R, Alì G, Proietti A, Fontanini G, Joseph A, Crinò L, Cappuzzo F. P1.01-015 Crizotinib in ROS1 Rearranged or MET Deregulated Non-Small-Cell Lung Cancer (NSCLC): Final Results of the METROS Trial. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.669] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
12
|
Landi L, Chiari R, Dazzi C, Tiseo M, Chella A, Delmonte A, Bonanno L, Cortinovis D, de Marinis F, Minuti G, Buosi R, Morabito A, Maione P, Galetta D, Barbieri F, Grossi F, Novello S, Bruno R, Fontanini G, Crinò L, Cappuzzo F. Crizotinib in ROS1 rearranged or MET deregulated non-small-cell lung cancer (NSCLC): final results of the METROS trial. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
13
|
Bossi P, Cortinovis D, Fatigoni S, Cossu Rocca M, Fabi A, Seminara P, Ripamonti C, Alfieri S, Granata R, Bergamini C, Agustoni F, Bidoli P, Nolè F, Pessi MA, Macchi F, Michellini L, Montanaro F, Roila F. A randomized, double-blind, placebo-controlled, multicenter study of a ginger extract in the management of chemotherapy-induced nausea and vomiting (CINV) in patients receiving high-dose cisplatin. Ann Oncol 2017; 28:2547-2551. [PMID: 28666335 DOI: 10.1093/annonc/mdx315] [Citation(s) in RCA: 30] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Abstract
BACKGROUND The activity of ginger in the management of chemotherapy-induced nausea and vomiting (CINV) has been suggested, but design inadequacies, heterogeneity of the population, small numbers and poor quality of tested products limit the possibility to offer generalizable results. PATIENTS AND METHODS We conducted a randomized, double-blind, placebo-controlled, multicenter study in patients planned to receive ≥2 chemotherapy cycles with high dose (>50 mg/m2) cisplatin. Patients received ginger 160 mg/day (with standardized dose of bioactive compounds) or placebo in addition to the standard antiemetic prophylaxis for CINV, starting from the day after cisplatin administration. CINV was assessed through daily visual-analogue scale and Functional Living Index Emesis questionnaires. The main objective was protection from delayed nausea; secondary end points included intercycle nausea and nausea anticipatory symptoms. RESULTS In total, 121 patients received ginger and 123 placebo. Lung (49%) and head and neck cancer (HNC; 35%) were the most represented tumors. No differences were reported in terms of safety profile or compliance. The incidence of delayed, intercycle and anticipatory nausea did not differ between the two arms in the first cycle and second cycle. A benefit of ginger over placebo in Functional Living Index Emesis nausea score differences (day 6-day 1) was identified for females (P = 0.048) and HNC patients (P = 0.038). CONCLUSIONS In patients treated with high-dose cisplatin, the daily addition of ginger, even if safe, did not result in a protective effect on CINV. The favorable effect observed on nausea in subgroups at particular risk of nausea (females; HNC) deserves specific investigation.
Collapse
Affiliation(s)
- P Bossi
- Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Scientific Direction, Latis Cro, Genova, Milano;.
| | | | - S Fatigoni
- Medical Oncology, Ospedale Santa Maria, Terni
| | - M Cossu Rocca
- Medical Oncology, Istituto Europeo di Oncologia, Milano
| | - A Fabi
- Medical Oncology, Istituto Nazionale Regina Elena, Roma
| | - P Seminara
- Medical Oncology, Università Sapienza, Roma
| | | | - S Alfieri
- Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Scientific Direction, Latis Cro, Genova, Milano
| | - R Granata
- Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Scientific Direction, Latis Cro, Genova, Milano
| | - C Bergamini
- Head and Neck Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Scientific Direction, Latis Cro, Genova, Milano
| | - F Agustoni
- Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy
| | - P Bidoli
- Medical Oncology, Ospedale San Gerardo, Monza
| | - F Nolè
- Medical Oncology, Istituto Europeo di Oncologia, Milano
| | | | - F Macchi
- Scientific & Clinical Development, Helsinn Integrative Care, Lugano, Switzerland
| | | | - F Montanaro
- Statistical Department, Latis Cro, Genova, Italy
| | - F Roila
- Medical Oncology, Ospedale Santa Maria, Terni
| |
Collapse
|
14
|
Morabito A, Cavanna L, Luciani A, Maione P, Bonanno L, Piazza E, Leo S, Cinieri S, Morgillo F, Burgio M, Ferrara D, Cortinovis D, Rosetti F, Costanzo R, Sandomenico C, Daniele G, Signoriello S, Piccirillo M, Gallo C, Perrone F, Gridelli C. Cisplatin in addition to single-agent first-line chemotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC): efficacy results of a joint analysis of the multicentre, randomized phase 3 MILES-3 and MILES-4 studies. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx421.003] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
15
|
von Pawel J, Syrigos K, Mazieres J, Cortinovis D, Dziadziuszko R, Gandara D, Conkling P, Goldschmidt J, Thomas C, Bordoni R, Kosty M, Braiteh F, Hu S, Ballinger M, Patel H, Gandhi M, Fehrenbacher L. Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx380.017] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
16
|
Schütte W, Barlesi F, Park K, Ciardiello F, Pawel J, Gadgeel S, Hida T, Kowalski D, Cobo Dols M, Cortinovis D, Leach J, Polikoff J, Gandara DR, Barrios C, Chen DS, He P, Ballinger M, Waterkamp D, Sandler A, Rittmeyer A. Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC. Pneumologie 2017. [DOI: 10.1055/s-0037-1598278] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Affiliation(s)
- W Schütte
- Klinik für Innere Medizin, Klinik für Innere Medizin II, Städtisches Krankenhaus Martha Maria, Halle (Saale)
| | - F Barlesi
- Assistance Publique Hôpitaux de Marseille, Aix Marseille University
| | - K Park
- Sungkyunkwan University School of Medicine
| | | | - J Pawel
- Asklepios-Fachkliniken München-Gauting
| | - S Gadgeel
- Karmanos Cancer Institute/Wayne State University
| | - T Hida
- Aichi Cancer Center Hospital
| | - D Kowalski
- Oncology Centre, Institute M. Sklodowska – Curie
| | - M Cobo Dols
- Medical Oncology Section, Hospital Regional Universitario Carlos Haya
| | | | | | - J Polikoff
- Southern California Permanente Medical Group
| | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Park K, Barlesi F, Ciardiello F, von Pawel J, Gadgeel S, Hida T, Kowalski D, Cobo Dols M, Cortinovis D, Leach J, Polikoff J, Gandara D, Barrios C, Chen D, He P, Kowanetz M, Ballinger M, Waterkamp D, Sandler A, Rittmeyer A. 438O Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw594.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
18
|
Barlesi F, Park K, Ciardiello F, von Pawel J, Gadgeel S, Hida T, Kowalski D, Dols M, Cortinovis D, Leach J, Polikoff J, Gandara D, Barrios C, Chen D, He P, Kowanetz M, Ballinger M, Waterkamp D, Sandler A, Rittmeyer A. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw435.43] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Gobbini E, Grecorc V, Galetta D, Riccardi F, Tiseo M, Scotti V, Ceribelli A, Buffoni L, Maiello E, Delmonte A, Franchina T, Migliorino M, Cortinovis D, Pisconti S, Di Maio M, Graziano P, Bria E, Rossi G, Rossi A, Novello S. Molecular profiling in advanced non-small-cell lung cancer: preliminary data of the Italian observational prospective study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
20
|
Abbate M, Tiseo M, Vavalà T, Cerea G, Cortinovis D, Toschi L, Canova S, Bidoli P. Peritoneal carcinomatosis in non-small celllung cancer: retrospective multicentric analysis. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.38] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
21
|
Bergamini C, Bergamini C, Cortinovis D, Fatigoni S, Cossu Rocca M, Fabi A, Iannace A, Emiliani A, Pessi M, Ripamonti C, Alfieri S, Granata R, Agustoni F, Bidoli P, Roila F, Nolé F, Macchi F, Michellini L, Montanaro F, Bossi P. Ginger in the management of chemotherapy induced nausea and vomiting (CINV), in patients receiving high dose cisplatin: a multicenter, randomized, double-blind, placebo-controlled study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw336.10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
22
|
Canova S, Bidoli P, Lissoni P, Abbate M, Capici S, Casiraghi S, Cortinovis D. Predictive role of absolute lymphocyte count (alc) and neutrophil/lymphocyte ratio (nlr) in patients with metastatic non small cell lung cancer (nsclc) treated with nivolumab: results of a retrospective monocentric study. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.29] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
23
|
Abstract
Non-small-cell lung cancer is still considered a difficult disease to manage because of its aggressiveness and resistance to common therapies. Chemotherapy remains the gold standard in nearly 80% of lung cancers, but clinical outcomes are discouraging, and the impact on median overall survival (OS) barely reaches 12 months. At the end of the last century, the discovery of oncogene-driven tumours completely changed the therapeutic landscape in lung cancers, harbouring specific gene mutations/translocations. Epidermal growth factors receptor (EGFR) common mutations first and anaplastic lymphoma kinase (ALK) translocations later led new insights in lung cancer biology knowledge. The use of specific tyrosine kinases inhibitors overturned the biological behaviour of EGFR mutation positive tumours and became a preclinical model to understand the heterogeneity of lung cancers and the mechanisms of drug resistance. In this review, we summarise the employment of targeted agents against the most representative biomolecular alterations and provide some criticisms of the therapeutic strategies.
Collapse
Affiliation(s)
- D Cortinovis
- Medical Oncology Unit, AOU San Gerardo, via Giambattista Pergolesi 33, 20900 Monza, Italy
| | - M Abbate
- Medical Oncology Unit, AOU San Gerardo, via Giambattista Pergolesi 33, 20900 Monza, Italy
| | - P Bidoli
- Medical Oncology Unit, AOU San Gerardo, via Giambattista Pergolesi 33, 20900 Monza, Italy
| | - S Capici
- Medical Oncology Unit, AOU San Gerardo, via Giambattista Pergolesi 33, 20900 Monza, Italy
| | - S Canova
- Medical Oncology Unit, AOU San Gerardo, via Giambattista Pergolesi 33, 20900 Monza, Italy
| |
Collapse
|
24
|
Girard N, Corral J, Cortinovis D, Heigener D. 183P: Second-line treatment selection in patients with non-small cell lung cancer of adenocarcinoma histology: A European survey. J Thorac Oncol 2016. [DOI: 10.1016/s1556-0864(16)30293-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
25
|
Ceresoli G, Zucali P, Grosso F, Mencoboni M, Sauta M, Soto Parra H, Pasello G, Cortinovis D, Perrino M, Muzio A, Bruzzone A, De Vincenzo F, Degiovanni D, Bonomi M, Simonelli M, Beretta G, Giordano L, Santoro A. Vinorelbine as second or third-line therapy in pemetrexed-pretreated malignant pleural mesothelioma (MPM) patients. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.13] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
26
|
Cortinovis D, Hollander L, Floriani I, Grosso F, Marinello A, Ceresoli G, Pacchetti I, Zucali P, Tiseo M, D'Incalci M, Canova S, Ugo F, Vukcaj S, Abbate M, Zai S, Bidoli P. Activity and Safety of Trabectedin in patients with Sarcomatoid / Biphasic Malignant Pleural Mesothelioma (MPM). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
27
|
Pacchiana M, Capelletto E, Rossi A, Galetta D, Bordi P, Ceribelli A, Scotti V, Cortinovis D, Valmadre G, Martelli O, Miccianza A, Del Conte A, Morena R, Rosetti F, Ostacoli L, Novello S. Maintenance Therapy (MT) for non-squamous advanced NSCLC: a multicenter Italian survey about patients (pts)' perspectives and physicians' awareness. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv347.07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
28
|
Normanno N, Morabito A, Novello S, Cortinovis D, Migliorino M, Pinto C, Pasquale R, Montanino A, Capelletto E, Tonini G, Bidoli P, Galetta D, Ricciardi S, Milella M, Melotti B, Romano G, Crinò L. Circulating-free tumor DNA as a surrogate for determination of EGFR status: the Italian experience within the ASSESS study. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
29
|
Hollander L, Cortinovis D, Floriani I, Grosso F, Ceresoli G, Zucali P, D'Incalci M, Tiseo M, Abbate M, Canova S, Ugo F, Marchini S, Allavena P, Bianchi M, Corli O, Vukcaj S, Zai S, Bidoli P. ATREUS Trial: A Phase II Study On The Activity Of Trabectedin In Pretreated Epithelioid Or Biphasic/Sarcomatoid Malignant Pleural Mesothelioma (MPM). Ann Oncol 2015. [DOI: 10.1093/annonc/mdv343.43] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
30
|
Vavala T, Novello S, Grossi F, Misino A, Cortinovis D, Valmadre G, Meoni G, Caffo O, Follador A, Bearz A, Trenta P, Gregorc V, Defferrari C, Cordero L, Colantonio I, Torri V, Monica V, Papotti M, Scagliotti G. A Randomized Phase III Multicenter Trial of Customized Chemotherapy Versus Standard of Care for 1St Line Treatment of Elderly Patients with Advanced Non-Small-Cell Lung Cancer (Nsclc): the Elderly Patient Individualized Chemotherapy (Epic) Trial. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.108] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Vavala T, Follador A, Tiseo M, Galetta D, Montanino A, Martelli O, Caffo O, Piovano P, Cortinovis D, Zilembo N, Casartelli C, Banna G, Colombo D, Barzelloni M, Rijavec E, Cecere F, Bria E, Lazzari C, Rossi A, Novello S. Be-Positive: Beyond Progression After Tyrosine Kinase Inhibitor in Egfr-Positive Non-Small Cell Lung Cancer (Nsclc) Patients. Preliminary Results from a Multicenter Italian Observational Study. Ann Oncol 2014. [DOI: 10.1093/annonc/mdu349.57] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Cortinovis D, Monica V, Pietrantonio F, Ceresoli G, Spina C, Wannesson L. MicroRNAs in Non-small Cell Lung Cancer: Current Status and Future Therapeutic Promises. Curr Pharm Des 2014; 20:3982-90. [DOI: 10.2174/13816128113196660755] [Citation(s) in RCA: 33] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/18/2013] [Accepted: 10/28/2013] [Indexed: 11/22/2022]
|
33
|
Binda D, Vanhoutte E, Cavaletti G, Cornblath D, Postma T, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou A, Kalofonos H, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Lalisang R, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Rossi E, Valsecchi M, Faber C, Merkies I, Galimberti S, Lanzani F, Mattavelli L, Piatti M, Bidoli P, Cazzaniga M, Cortinovis D, Lucchetta M, Campagnolo M, Bakkers M, Brouwer B, Boogerd W, Grant R, Reni L, Piras B, Pessino A, Padua L, Granata G, Leandri M, Ghignotti I, Plasmati R, Pastorelli F, Heimans J, Eurelings M, Meijer R, Grisold W, Lindeck Pozza E, Mazzeo A, Toscano A, Russo M, Tomasello C, Altavilla G, Penas Prado M, Dominguez Gonzalez C, Dorsey S. Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS). Eur J Cancer 2013; 49:2910-8. [DOI: 10.1016/j.ejca.2013.04.004] [Citation(s) in RCA: 32] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/11/2013] [Revised: 04/03/2013] [Accepted: 04/05/2013] [Indexed: 10/26/2022]
|
34
|
Ceresoli GL, Zucali PA, Mencoboni M, Botta M, Grossi F, Cortinovis D, Zilembo N, Ripa C, Tiseo M, Favaretto AG, Soto-Parra H, De Vincenzo F, Bruzzone A, Lorenzi E, Gianoncelli L, Ercoli B, Giordano L, Santoro A. Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma. Br J Cancer 2013; 109:552-8. [PMID: 23860535 PMCID: PMC3738125 DOI: 10.1038/bjc.2013.368] [Citation(s) in RCA: 78] [Impact Index Per Article: 7.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/24/2013] [Revised: 06/10/2013] [Accepted: 06/22/2013] [Indexed: 12/21/2022] Open
Abstract
Background: The aim of this open label phase II study (NCT00407459) was to assess the activity of the vascular endothelial growth factor (VEGF) inhibitor bevacizumab combined with pemetrexed and carboplatin in patients with previously untreated, unresectable malignant pleural mesothelioma (MPM). Methods: Eligible patients received pemetrexed 500 mg m−2, carboplatin area under the plasma concentration–time curve (AUC) 5 mg ml−1 per minute and bevacizumab 15 mg kg−1, administered intravenously every 21 days for six cycles, followed by maintenance bevacizumab. The primary end point of the study was progression-free survival (PFS). A 50% improvement in median PFS in comparison with standard pemetrexed/platinum combinations (from 6 to 9 months) was postulated. Results: Seventy-six patients were evaluable for analysis. A partial response was achieved in 26 cases (34.2%, 95% CI 23.7–46.0%). Forty-four (57.9%, 95% CI 46.0–69.1%) had stable disease. Median PFS and overall survival were 6.9 and 15.3 months, respectively. Haematological and non-haematological toxicities were generally mild; however, some severe adverse events were reported, including grade 3–4 fatigue in 8% and bowel perforation in 4% of patients. Three toxic deaths occurred. Conclusion: The primary end point of the trial was not reached. However, due to the limitation of a non-randomised phase II design, further data are needed before drawing any definite conclusion on the role of bevacizumab in MPM.
Collapse
Affiliation(s)
- G L Ceresoli
- Department of Medical Oncology, Cliniche Humanitas Gavazzeni, Bergamo, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
35
|
Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Faber CG, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Valsecchi MG, Mazzeo A, Pace A, Pessino A, Schenone A, Toscano A, Argyriou AA, Brouwer B, Frigeni B, Piras B, Briani C, Dalla Torre C, Dominguez Gonzalez C, Faber CG, Tomasello C, Binda D, Brandsma D, Cortinovis D, Psimaras D, Ricard D, Storey D, Cornblath DR, Galiè E, Lindeck Pozza E, Rossi E, Vanhoutte EK, Lanzani F, Pastorelli F, Altavilla G, Cavaletti G, Granata G, Kalofonos HP, Ghignotti I, Merkies ISJ, Bruna J, Hense J, Heimans JJ, Mattavelli L, Padua L, Reni L, Bakkers M, Boogerd M, Campagnolo M, Cazzaniga M, Eurelings M, Leandri M, Lucchetta M, Penas Prado M, Russo M, Valsecchi MG, Piatti ML, Alberti P, Bidoli P, Grant R, Plasmati R, Velasco R, Lalisang RI, Meijer RJ, Fabbri S, Dorsey SG, Galimberti S, Kerrigan S, Koeppen S, Postma TJ, Boogerd W, Grisold W. The chemotherapy-induced peripheral neuropathy outcome measures standardization study: from consensus to the first validity and reliability findings. Ann Oncol 2013; 24:454-462. [PMID: 22910842 PMCID: PMC3551481 DOI: 10.1093/annonc/mds329] [Citation(s) in RCA: 208] [Impact Index Per Article: 18.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2012] [Revised: 06/05/2012] [Accepted: 07/09/2012] [Indexed: 01/12/2023] Open
Abstract
BACKGROUND Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating and dose-limiting complication of cancer treatment. Thus far, the impact of CIPN has not been studied in a systematic clinimetric manner. The objective of the study was to select outcome measures for CIPN evaluation and to establish their validity and reproducibility in a cross-sectional multicenter study. PATIENTS AND METHODS After literature review and a consensus meeting among experts, face/content validity were obtained for the following selected scales: the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), the Total Neuropathy Score clinical version (TNSc), the modified Inflammatory Neuropathy Cause and Treatment (INCAT) group sensory sumscore (mISS), the European Organization for Research and Treatment of Cancer (EORTC) QLQ-C30, and CIPN20 quality-of-life measures. A total of 281 patients with stable CIPN were examined. Validity (correlation) and reliability studies were carried out. RESULTS Good inter-/intra-observer scores were obtained for the TNSc, mISS, and NCI-CTC sensory/motor subscales. Test-retest values were also good for the EORTC QLQ-C30 and CIPN20. Acceptable validity scores were obtained through the correlation among the measures. CONCLUSION Good validity and reliability scores were demonstrated for the set of selected impairment and quality-of-life outcome measures in CIPN. Future studies are planned to investigate the responsiveness aspects of these measures.
Collapse
Affiliation(s)
- G Cavaletti
- Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Monza, Italy.
| | - D R Cornblath
- Department of Neurology, Johns Hopkins University, School of Medicine, Baltimore, MD, USA
| | - I S J Merkies
- Department of Neurology, Spaarne Hospital, Hoofddorp/Maastricht, University Medical Center, Maastricht
| | - T J Postma
- Department of Neurology, VU University Medical Center, Amsterdam, The Netherlands
| | - E Rossi
- Center of Biostatistics for Clinical Epidemiology, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy
| | - B Frigeni
- Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Monza, Italy
| | - P Alberti
- Department of Neuroscience and Biomedical Technologies, University of Milano-Bicocca, Monza, Italy
| | - J Bruna
- Unit of Neuro-Oncology, Department of Neurology, University Hospital of Bellvitge, L'Hospitalet, Spain
| | - R Velasco
- Unit of Neuro-Oncology, Department of Neurology, University Hospital of Bellvitge, L'Hospitalet, Spain
| | - A A Argyriou
- Division of Clinical Oncology, Department of Medicine, University Hospital of Patras, Patras, Greece
| | - H P Kalofonos
- Division of Clinical Oncology, Department of Medicine, University Hospital of Patras, Patras, Greece
| | - D Psimaras
- Service de Neurologie Mazarin, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris
| | - D Ricard
- Service de Neurologie, Hôpital du Val-de-Grâce, Service de Santé des Armées, Paris, France
| | - A Pace
- Neurology Unit, National Cancer Institute Regina Elena, Rome
| | - E Galiè
- Neurology Unit, National Cancer Institute Regina Elena, Rome
| | - C Briani
- Department of Neurosciences, University of Padova, Padova, Italy
| | - C Dalla Torre
- Department of Neurosciences, University of Padova, Padova, Italy
| | - C G Faber
- Department of Neurology, Spaarne Hospital, Hoofddorp/Maastricht, University Medical Center, Maastricht
| | - R I Lalisang
- Division of Medical Oncology, Department of Internal Medicine, GROW-School of Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht
| | - W Boogerd
- Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - D Brandsma
- Department of Neuro-oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - S Koeppen
- Department of Neurology and West German Cancer Center, University of Essen, Essen, Germany
| | - J Hense
- Department of Neurology and West German Cancer Center, University of Essen, Essen, Germany
| | - D Storey
- Edinburgh Centre for Neuro-Oncology and Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK
| | - S Kerrigan
- Edinburgh Centre for Neuro-Oncology and Edinburgh Cancer Research Centre, Western General Hospital, Edinburgh, UK
| | - A Schenone
- Department of Neurosciences, Ophthalmology and Genetic, Center of Excellence for Biomedical Research, University of Genova, Genova, Italy
| | - S Fabbri
- Department of Neurosciences, Ophthalmology and Genetic, Center of Excellence for Biomedical Research, University of Genova, Genova, Italy
| | - M G Valsecchi
- Center of Biostatistics for Clinical Epidemiology, Department of Clinical Medicine and Prevention, University of Milano-Bicocca, Monza, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
36
|
Argyriou AA, Briani C, Cavaletti G, Bruna J, Alberti P, Velasco R, Lonardi S, Cortinovis D, Cazzaniga M, Campagnolo M, Santos C, Kalofonos HP. Advanced age and liability to oxaliplatin-induced peripheral neuropathy:post hocanalysis of a prospective study. Eur J Neurol 2012; 20:788-94. [DOI: 10.1111/ene.12061] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2012] [Accepted: 11/01/2012] [Indexed: 11/27/2022]
Affiliation(s)
| | - C. Briani
- Department of Neurosciences; University of Padova; Padova; Italy
| | - G. Cavaletti
- Department of Neuroscience and Biomedical Technology; University of Milan-Bicocca; Monza; Italy
| | - J. Bruna
- Unit of Neuro-Oncology; University Hospital of Bellvitge-ICO Duran i Reynals; Barcelona; Spain
| | - P. Alberti
- Department of Neuroscience and Biomedical Technology; University of Milan-Bicocca; Monza; Italy
| | - R. Velasco
- Unit of Neuro-Oncology; University Hospital of Bellvitge-ICO Duran i Reynals; Barcelona; Spain
| | - S. Lonardi
- Oncology Unit 1; Veneto Oncology Institute - IRCCS; Padova; Italy
| | | | | | - M. Campagnolo
- Department of Neurosciences; University of Padova; Padova; Italy
| | - C. Santos
- Unit of Colorectal Cancer; University Hospital of Bellvitge-ICO Duran i Reynals; Barcelona; Spain
| | - H. P. Kalofonos
- Department of Medicine-Division of Clinical Oncology; University Hospital of Patras; Rion-Patras; Greece
| |
Collapse
|
37
|
Argyriou AA, Velasco R, Briani C, Cavaletti G, Bruna J, Alberti P, Cacciavillani M, Lonardi S, Santos C, Cortinovis D, Cazzaniga M, Kalofonos HP. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 2012; 23:3116-3122. [PMID: 22865779 DOI: 10.1093/annonc/mds208] [Citation(s) in RCA: 63] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND To report our prospective experience on the incidence and pattern of oxaliplatin (OXA)-induced peripheral neuropathy (OXA-IPN) in patients with colorectal cancer (CRC) treated with either FOLFOX-4 or XELoda + OXaliplatin (XELOX). PATIENTS AND METHODS One hundred and fifty patients scheduled to be treated with either FOLFOX or XELOX for CRC were prospectively monitored at baseline and followed-up during chemotherapy. The incidence and severity of symptoms secondary to OXA-IPN were recorded using three different types of assessment, i.e. the motor and neurosensory National Cancer Institute common toxicity criteria, version 3.0 (NCI-CTCv3), the clinical version of the total neuropathy score (TNSc) and electrophysiological scores. RESULTS Patients treated with either FOLFOX-4 or XELOX manifested similar incidence rates and severities of acute OXA-IPN. However, FOLFOX-4 was associated with increased incidence of chronic neurotoxicity, compared with XELOX-treated patients (n = 64/77 versus 44/73; P = 0.002), at a very similar OXA median cumulative dose during both regimens. Both the NCI-CTCv3 and TNSc demonstrated that the severity of cumulative OXA-IPN in FOLFOX-4-treated patients is higher than in those treated with XELOX. CONCLUSION The incidence of acute neurotoxicity during FOLFOX-4 therapy is similar to XELOX. However, it seems that FOLFOX-4 is more neurotoxic than XELOX in terms of cumulative OXA-IPN, despite comparable OXA cumulative dose.
Collapse
Affiliation(s)
- A A Argyriou
- Department of Neurology, 'Saint Andrew's" State General Hospital of Patras, Patras; Department of Medicine-Division of Clinical Oncology, University Hospital of Patras, Rion-Patras, Greece
| | - R Velasco
- Department of Neurology-Unit of Neuro-Oncology, University Hospital of Bellvitge-ICO Duran i Reynals, Barcelona, Spain
| | - C Briani
- Department of Neurosciences, University of Padova, Padova
| | - G Cavaletti
- Department of Neuroscience and Biomedical Technology, University of Milan-Bicocca, Monza
| | - J Bruna
- Department of Neurology-Unit of Neuro-Oncology, University Hospital of Bellvitge-ICO Duran i Reynals, Barcelona, Spain
| | - P Alberti
- Department of Neuroscience and Biomedical Technology, University of Milan-Bicocca, Monza
| | | | - S Lonardi
- Oncology Unit 1, Veneto Oncology Institute - IRCCS, Padova, Italy
| | - C Santos
- Department of Oncology-Unit of Colorectal Cancer, University Hospital of Bellvitge-ICO Duran i Reynals, Barcelona, Spain
| | - D Cortinovis
- Department of Oncology, S. Gerardo Hospital, Monza, Italy
| | - M Cazzaniga
- Department of Oncology, S. Gerardo Hospital, Monza, Italy
| | - H P Kalofonos
- Department of Neurology-Unit of Neuro-Oncology, University Hospital of Bellvitge-ICO Duran i Reynals, Barcelona, Spain.
| |
Collapse
|
38
|
Cazzaniqa M, Baronchelli S, Bovo G, Pellizzoni D, Crosti F, Giuntini N, Villa F, Cortinovis D, Bidoli P. 6131 POSTER Evaluation of BRAF Mutational Status in Wild Type (WT) KRAS Metastatic Colon-Rectal Cancer (MCRC) Patients (pts) Treated With Cetuximab (C) – a Single Institution Experience. Eur J Cancer 2011. [DOI: 10.1016/s0959-8049(11)71776-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
|
39
|
Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 2011; 71:249-57. [PMID: 21216486 DOI: 10.1016/j.lungcan.2010.12.008] [Citation(s) in RCA: 87] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2010] [Revised: 12/10/2010] [Accepted: 12/18/2010] [Indexed: 01/09/2023]
Abstract
Gefitinib is a small molecule tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR). Since 2004, it was clear that a substantial proportion of non-small-cell lung cancers (NSCLC) obtaining objective response when treated with gefitinib harbour activating mutations in the EGFR gene. Consequently, EGFR mutation has been widely studied, together with other molecular characteristics, as a potential predictive factor for gefitinib efficacy. As of August 2010, four East Asian randomized phase III trials comparing gefitinib to platinum-based chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) eligible for first-line treatment have been reported or published. Two of these trials were conducted without a molecular selection in patients with clinical characteristics (adenocarcinoma histology, never or light smoking) characterized by higher prevalence of EGFR mutation. In patients selected for the presence of tumor harbouring EGFR mutation, the administration of first-line gefitinib, as compared to standard chemotherapy, was associated with longer progression-free survival, higher objective response rate, a more favourable toxicity profile and better quality of life. The relevant improvement in progression-free survival with first-line administration of gefitinib has been confirmed in the other two randomized trials, dedicated to cases with EGFR mutation. In July 2009, European Medicines Agency granted marketing authorization for gefitinib for the treatment of locally advanced or metastatic NSCLC with sensitizing mutations of the EGFR gene, across all lines of therapy. Gefitinib currently represents the best first-line treatment option for this molecularly selected subgroup of patients.
Collapse
Affiliation(s)
- C Gridelli
- Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy.
| | | | | | | | | | | |
Collapse
|
40
|
Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating Epidermal Growth Factor Receptor mutation: implications for clinical practice and open issues. Lung Cancer 2011; 72:3-8. [PMID: 21216488 DOI: 10.1016/j.lungcan.2010.12.009] [Citation(s) in RCA: 38] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2010] [Revised: 12/10/2010] [Accepted: 12/18/2010] [Indexed: 01/28/2023]
Abstract
Randomized trials comparing gefitinib with chemotherapy as first-line treatment in patients with EGFR mutated advanced NSCLC support gefitinib as a new, highly effective treatment option in this setting. However, its use in clinical practice has several relevant implications and open issues. In order to choose the best treatment, a molecular characterization is now mandatory, as part of baseline diagnostic procedures. Every effort should be made in order to obtain sufficient tissue. If a clinical enrichment has to be performed for selecting patients to test for EGFR mutation, a reasonable proposal is to test all non-squamous tumors, and patients with squamous tumors only if never smokers. In patients with EGFR mutated tumor, one major issue is the decision about immediate use of gefitinib as first-line, or after failure of standard chemotherapy. First-line gefitinib, compared to chemotherapy, is associated with longer progression-free survival, higher response rate, better toxicity profile and quality of life, and its administration as first-line warrants that all patients have the chance of receiving an EGFR inhibitor. Evidence about the efficacy of erlotinib in the same setting will be soon available, however, at the moment, there are no direct comparisons between gefitinib and erlotinib in EGFR mutated patients. Treatment with gefitinib is usually well tolerated. Typical side effects in most cases are of mild to moderate intensity, and usually manageable with temporary interruption of treatment. When indicated gefitinib appears feasible also in special populations, like elderly or unfit patients, characterized by a significantly poorer risk/benefit ratio with standard chemotherapy. Personalized medicine for patients with lung cancer is now a reality, and patients with EGFR mutation should be treated with first-line EGFR tyrosine kinase inhibitor.
Collapse
Affiliation(s)
- C Gridelli
- Division of Medical Oncology, SG Moscati Hospital, Avellino, Italy.
| | | | | | | | | | | |
Collapse
|
41
|
Cazzaniga ME, Torri V, Villa F, Giuntini N, Zeppelini A, Cortinovis D, Bidoli P. Abstract P6-11-10: Full-Oral, Metronomic Schedule of Vinorelbine (VNB) and Capecitabine (CAPE) in Locally Advanced or Metastatic Breast Cancer (BC) Patients (Pts): A Single Institution, Dose-Finding Study. Cancer Res 2010. [DOI: 10.1158/0008-5472.sabcs10-p6-11-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND: Choice of chemotherapy is a major problem in locally advanced (LABC) or metastatic BC pts already treated with anthracyclines and taxanes, or not suitable for these drugs. VNB and CAPE are two valid options, both tested as single agents or in combination in this setting of pts. Different studies have demonstrated that the metronomic treatment could achieve a significant rate of clinical response with an acceptable toxicity profile. Based on the results of metronomic Phase I/II trial, which fixed the dose of VNB at 60 mg/tot thrice a week and considering that the two drugs have a different safety profile, we designed a dose-finding study, aiming to determine the optimal dose of oral VNB in combination with CAPE, both administered in a metronomic way. PATIENTS AND METHODS: Fixed dose of CAPE was 500 mg thrice a day, continuously. Level I dose of VNB was 20 mg/tot, three times a week for 3 weeks (1 cycle); subsequent cohorts started with 30 mg/tot Level II), 40 mg/tot (Level III) and 50 mg/tot (Level IV), respectively, if no Grade 3-4 toxicity was observed in the same dose level of the previous cohort.
Results: Twelve consecutive pts were enrolled. Median age was 67.5 years (49-81), 4 pts were LABC or metastatic at diagnosis, HR status was positive in 11/12 pts (91.6%), 2 pts were HER2+ but could not or no longer receive antiHER2 agents due to cardiac failure. All pts but 2 (83.3%) received anthracyclines, taxanes or both. Mean number of metastatic sites was 3 (1-5). At the 50 mg level of dose, 1 pt developed G3 neurological toxicity during the 3rd week of cycle 1 and 1 pt G4 neutropenia in the 2nd week of cycle 2. No pts treated with the 40 mg level of dose experienced G3 toxicity. The Maximum Tolerated Dose (MTD) was fixed at 40 mg thrice a week.
CONCLUSION: MTD of metronomic full-oral schedule of VNB in combination with fixed dose of CAPE was 40 mg thrice a week and was the recommended dose for the further ongoing Phase II study.
Citation Information: Cancer Res 2010;70(24 Suppl):Abstract nr P6-11-10.
Collapse
Affiliation(s)
- ME Cazzaniga
- AO S Gerardo, Monza, MB, Italy; Istituto Mario Negri, Milano, MI, Italy
| | - V Torri
- AO S Gerardo, Monza, MB, Italy; Istituto Mario Negri, Milano, MI, Italy
| | - F Villa
- AO S Gerardo, Monza, MB, Italy; Istituto Mario Negri, Milano, MI, Italy
| | - N Giuntini
- AO S Gerardo, Monza, MB, Italy; Istituto Mario Negri, Milano, MI, Italy
| | - A Zeppelini
- AO S Gerardo, Monza, MB, Italy; Istituto Mario Negri, Milano, MI, Italy
| | - D Cortinovis
- AO S Gerardo, Monza, MB, Italy; Istituto Mario Negri, Milano, MI, Italy
| | - P. Bidoli
- AO S Gerardo, Monza, MB, Italy; Istituto Mario Negri, Milano, MI, Italy
| |
Collapse
|
42
|
Ceresoli GL, Castagneto B, Zucali PA, Favaretto A, Mencoboni M, Grossi F, Cortinovis D, Del Conte G, Ceribelli A, Bearz A, Salamina S, De Vincenzo F, Cappuzzo F, Marangolo M, Torri V, Santoro A. Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials. Br J Cancer 2008; 99:51-6. [PMID: 18542071 PMCID: PMC2453025 DOI: 10.1038/sj.bjc.6604442] [Citation(s) in RCA: 93] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Revised: 04/15/2008] [Accepted: 04/24/2008] [Indexed: 12/23/2022] Open
Abstract
The incidence of malignant pleural mesothelioma (MPM) in elderly patients is increasing. In this study, pooled data from two phase II trials of pemetrexed and carboplatin (PC) as first-line therapy were retrospectively analysed for comparisons between age groups. Patients received pemetrexed 500 mg m(-2) and carboplatin AUC 5 mg ml(-1) min(-1) intravenously every 21 days with standard vitamin supplementation. Elderly patients were defined as those >or=70 years old. A total of 178 patients with an ECOG performance status of or=70 years (27%). Grade 3-4 haematological toxicity was slightly worse in >or=70 vs <70-year-old patients, with neutropenia observed in 25.0 vs 13.8% (P=0.11), anaemia in 20.8 vs 6.9% (P=0.01) and thrombocytopenia in 14.6 vs 8.5% (P=0.26). Non-haematological toxicity was mild and similar in the two groups. No significant difference was observed in terms of overall disease control (60.4 vs 66.9%, P=0.47), time to progression (7.2 vs 7.5 months, P=0.42) and survival (10.7 vs 13.9 months, P=0.12). Apart from slightly worse haematological toxicity, there was no significant difference in outcome or toxicity between age groups. The PC regimen is effective and well tolerated in selected elderly patients with MPM.
Collapse
Affiliation(s)
- G L Ceresoli
- Department of Oncology, Istituto Clinico Humanitas IRCCS, Rozzano, Milano, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
43
|
Gevorgyan A, Di Bartolomeo M, Andreola S, Orsenigo M, Casieri P, Signoroni S, Cortinovis D, Martinetti A, Pilotti S, Bajetta E. Epidermal Growth Factor Receptor (EGFr) status detection in correlation to objective response on cetuximab-based therapy in patients (pts) with advanced colorectal cancer (ACC). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.21070] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
21070 Background: In current clinical practice Cetuximab represents a standard therapy for Irinotecan resistant pts with ACC, where EGFR-immunohistochemistry (IHC) evaluation is positive. In absence of reliable molecular predictors of the clinical benefit to anti-EGFR therapy, we have studied EGFR protein expression and gene status in order to correlate them to the clinical response. Methods: We investigated 40 primary colorectal carcinoma specimens. EGFR-protein expression was evaluated by Immunohistochemistry (IHC) using PharmDX-Kit DAKO Cytomation. IHC evaluation was performed using combined score based on the sum of percentage of positive cells and the staining of each sample. We identified three EGFR-score categories: 0–2, 3–5, 6–7 corresponding to low, intermediate and high expression respectively. EGFR-genetic status was conducted by Dual-Colour FISH (LSI EGFR-probe Vysis Inc).Gene and chromosome 7 copy numbers were identified by fluorescence in situ hybridization (FISH-LSI EGFR-Dual-colour-probe Vysis-Inc) as follows: tumor samples had a high EGFR-gene copy number if there was high polysomy ( 4-copies 40% of cells) or gene amplification (gene-clusters, gene/chromosome ratio per cell of 2, 15 copies of EGFR/ cell in 10% of cells) . The analysis of clinical data from all patients treated with Cetuximab (400–250mg/m2/w) and Irinotecan (300mg/m2/d1q21) was then performed. Results: EGFR-(IHC) high score was observed in 7pts from which only 2 had an objective response (OR). Intermediate (13pts) with 3 OR, low (12pts) with 1 OR and negative (8pts) with 2OR. Main FISH patterns were: high polisomy/amplification in 8pts with no response on cetuximab therapy. Low polisomy described in 19pts with 3 cases of disease remission. Disomy in 13pts with 5OR. No relationship was detected between IHC-score evaluation and FISH pattern. The clinical benefit (OR+stable disease =6months) was 65% in score-group 0–2; whereas 46% and 57% in groups 3–5/6–7 respectively, without statistical significance. Conclusion: According to our experience, IHC and FISH are unable to provide adequate selection criteria for the patients with different EGFR-status expression, who can benefit from Cetuximab therapy. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Gevorgyan
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | | | - S. Andreola
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - M. Orsenigo
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - P. Casieri
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S. Signoroni
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - D. Cortinovis
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - A. Martinetti
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - S. Pilotti
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| | - E. Bajetta
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
| |
Collapse
|
44
|
Bidoli P, Zilembo N, Cortinovis D, Mariani L, Isa L, Aitini E, Cullurà D, Pari F, Nova P, Mancin M, Formisano B, Bajetta E. Randomized phase II three-arm trial with three platinum-based doublets in metastatic non-small-cell lung cancer. An Italian Trials in Medical Oncology study. Ann Oncol 2007; 18:461-7. [PMID: 17110590 DOI: 10.1093/annonc/mdl415] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Many patients with advanced non-small-cell lung cancer (NSCLC) do not tolerate cisplatin-based regimens because of its nonhemathological toxicity. PATIENTS AND METHODS We evaluated the response rate safety of new platinum analogue regimens, randomizing 147 patients with nonoperable IIIB/IV NSCLC to (i) carboplatin (area under the curve = 5 mg min/ml) on day 1 plus gemcitabine (GEM) (1000 mg/m(2)) on days 1 and 8 for six cycles; (ii) same regimen for three cycles followed by docetaxel (Taxotere) (40 mg/m(2)) on days 1 and 8 plus GEM (1250 mg/m(2)) on days 1 and 8 for three cycles; (iii) oxaliplatin (130 mg/m(2)) on day 1 plus GEM (1250 mg/m(2)) on days 1 and 8 for six cycles. RESULTS Intention-to-treat objective response rates were 25%, 25% and 30.6% in arms A, B and C, respectively. Median survival was 11.9, 9.2 and 11.3 months in arms A, B and C, respectively. Grade 3/4 neutropenia/anemia occurred in 29%/12.5%, 10%/16.5% and 8%/6% of arms A, B and C, respectively; grade 3/4 thrombocytopenia in 20.5%, 16.5% and 6%; grade 1/2 neurological toxicity in 43% of arm C. CONCLUSIONS Oxaliplatin/GEM (arm C) had similar activity to carboplatin/GEM (arm A), but milder hematological toxicity and may be worth testing in a phase III study against carboplatin/GEM in patients not suitable for cisplatin. The sequential regimen gave no additional benefit.
Collapse
Affiliation(s)
- P Bidoli
- Medical Oncology Unit 2, Fondazione IRCCS Istituto Nazionale dei Tumori i, Milan, Italy
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
45
|
Ceresoli G, Castagneto B, Zucali P, Favaretto A, Mencoboni M, De Giovanni D, Cortinovis D, Marangolo M, Grossi F, Del Conte G, Ceribelli A, Bearz A, Muzio A, Santoro A. 191 Pemetrexed in combination with carboplatin in elderly patients with malignant pleural mesothelioma. Lung Cancer 2006. [DOI: 10.1016/s0169-5002(07)70267-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
46
|
Bidoli P, Cortinovis D, Isa L, Fusi A, Pari F, Cullurà D, Aitini E, Pessa S, Formisano B, Bajetta E. Preliminary results of a randomized phase II three-arm, multicentric study of carboplatin + gemcitabine (CBDCA + GEM), or oxaliplatin (L-OHP) + GEM, or sequential CBDCA + GEM→ docetaxel (DCT) + GEM in chemo-naive patients (pts) with advanced/metastatic non small cell lung cancer (NSCLC). J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.7118] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- P. Bidoli
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - D. Cortinovis
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - L. Isa
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - A. Fusi
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - F. Pari
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - D. Cullurà
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - E. Aitini
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - S. Pessa
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - B. Formisano
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| | - E. Bajetta
- Inst Nazionale Tumori, Milan, Italy; Hosp. Serbelloni, Gorgonzola (MI), Italy; Hosp. C. Poma, Mantova, Italy; Hosp. Cà Foncello, Treviso, Italy
| |
Collapse
|
47
|
Bajetta E, Stani SC, De Candis D, Zaffaroni N, Zilembo N, Cortinovis D, Aglione S, Mariani L, Formisano B, Bidoli P. Preclinical and clinical evaluation of four gemcitabine plus carboplatin schedules as front-line treatment for stage IV non-small-cell lung cancer. Ann Oncol 2003; 14:242-7. [PMID: 12562651 DOI: 10.1093/annonc/mdg060] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND To explore the activity and tolerability of gemcitabine (GEM) and carboplatin (CBDCA) in non-small-cell lung cancer (NSCLC) we tested four administration sequences on H460 NSCLC cells, and at the same time performed a randomized phase II trial using analogous schedules. PATIENTS AND METHODS GEM was given first in two in vitro sequences, and CBDCA first in the other two; interaction was quantified calculating a combination index. Eighty-eight chemotherapy-naïve, stage IV NSCLC patients were randomly assigned to receive either: GEM (1000 mg/m(2)) on days 1 and 8 and CBDCA (AUC 5 mg.min/ml) on day 1, 4 h before GEM (arm A); same as arm A except CBDCA given 4 h after GEM (arm B); GEM on days 1 and 8 and CBDCA on day 2 (arm C); GEM on days 2 and 9 and CBDCA on day 1 (arm D). Courses were repeated every 21 days. RESULTS In the preclinical study, CBDCA given before GEM produced a synergistic cytotoxic effect. Two complete and 29 partial responses occurred in 86 of 88 treated patients (intention-to-treat analysis 35%; 95% confidence interval 25.5% to 46.8%). One- and 2-year survivals were 44% and 11%, respectively. Grade 3/4 thrombocytopenia occurred in 11%; grade 3/4 neutropenia in 17%; and non-hematological toxicity was insignificant. Median survival was 11 months (range 7-18+), but better in patients receiving CBDCA first (arms A and D) (13 versus 9 months) than in patients receiving GEM first (arms B and C). The response was greater (50% versus 31%) in arm A than in the other arms. CONCLUSIONS The CBDCA/GEM combination is safe and active against stage IV NSCLC. Our preclinical and clinical findings suggest that administration of CBDCA before GEM gives the better outcome.
Collapse
Affiliation(s)
- E Bajetta
- Medical Oncology Unit B, Unit of Experimental Oncology C, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
48
|
Bajetta E, Cortinovis D, Cassata A, Siena S, Cartei G, Pinotti G, Carreca L, Lambiase A. Activity and safety of capecitabine and irinotecan (CPT-11) in association as first line chemotherapy in advanced colorectal cancer (ACRC). Eur J Cancer 2001. [DOI: 10.1016/s0959-8049(01)81573-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
49
|
Bajetta E, Cassata A, Cortinovis D. [New drugs in the therapy of colorectal cancer]. Tumori 2001; 87:S3-4. [PMID: 11300017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/19/2023]
|